With its groundbreaking tauopathy therapeutics program, Treventis has demonstrated how CCM can enable protein misfolding drug design. The company is expanding its CCM platform into other indications including in oncology and other neurodegenerative disorders.

 Alzheimer’s Disease and Tauopathy  Amyotrophic Lateral Sclerosis (ALS)  Parkinson’s Disease Cancer  Dual Aβ/ tau oligomer inhibitor  Broad spectrum TDP oligomer inhibitor  p53 oligomer inhibitor